ABOS vs. ESPR, PROK, CRVS, TKNO, ANNX, MBX, CADL, AQST, SEPN, and ITOS
Should you be buying Acumen Pharmaceuticals stock or one of its competitors? The main competitors of Acumen Pharmaceuticals include Esperion Therapeutics (ESPR), ProKidney (PROK), Corvus Pharmaceuticals (CRVS), Alpha Teknova (TKNO), Annexon (ANNX), MBX Biosciences (MBX), Candel Therapeutics (CADL), Aquestive Therapeutics (AQST), Septerna (SEPN), and iTeos Therapeutics (ITOS). These companies are all part of the "pharmaceutical products" industry.
Acumen Pharmaceuticals vs.
Esperion Therapeutics (NASDAQ:ESPR) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, community ranking, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.
Esperion Therapeutics received 602 more outperform votes than Acumen Pharmaceuticals when rated by MarketBeat users. However, 71.43% of users gave Acumen Pharmaceuticals an outperform vote while only 70.21% of users gave Esperion Therapeutics an outperform vote.
Acumen Pharmaceuticals has a net margin of 0.00% compared to Esperion Therapeutics' net margin of -29.37%. Esperion Therapeutics' return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity.
Esperion Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.02, meaning that its share price is 98% less volatile than the S&P 500.
Esperion Therapeutics presently has a consensus target price of $6.75, indicating a potential upside of 319.25%. Acumen Pharmaceuticals has a consensus target price of $9.33, indicating a potential upside of 658.81%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than Esperion Therapeutics.
Acumen Pharmaceuticals has lower revenue, but higher earnings than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Esperion Therapeutics had 3 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 10 mentions for Esperion Therapeutics and 7 mentions for Acumen Pharmaceuticals. Esperion Therapeutics' average media sentiment score of 0.76 beat Acumen Pharmaceuticals' score of 0.11 indicating that Esperion Therapeutics is being referred to more favorably in the media.
47.4% of Esperion Therapeutics shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 1.0% of Esperion Therapeutics shares are held by insiders. Comparatively, 7.1% of Acumen Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Esperion Therapeutics and Acumen Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get Acumen Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acumen Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ABOS) was last updated on 3/28/2025 by MarketBeat.com Staff
Buy ABOS Stock Free ABOS Stock Alerts